Affimed NV (NASDAQ: AFMD) has given an update about its corporate and clinical progress. Cancer happens to be one of the deadliest conditions worldwide, and the company seeks to contribute positively towards the fight.
Dr. Adi Hoess and his perspective on matters
The CEO of Affimed, Dr. Adi Hoess, opines, “Over the next several months, we have a number of value-creating events on AFM13, AFM24, where we expect to initiate several clinical studies, and AFM28, and are allocating capital across our portfolio to develop multiple opportunities for shareholder value creation.”
Updates on the clinical stage program
Affirmed says it will continue with the recruitment of more patients in its REDIRECT study. It makes this announcement a short time after its preplanned interim futility analysis in March 2021 presented some desirable outcomes. The company had been quick to announce the positive results but now wants to add more new patients.
Affirmed conducted an elaborate trial that struck a combination between the high- and low-CD30 expressing cohorts and looks forward to doing what is necessary to achieve remarkable outcomes. It projects that it might come to the end of its enrolment exercise somewhere in the first half of 2022.
REDIRECT happens to be a registration-directed study of AFM13 in phase 2. It is meant to serve as a monotherapy to treat patients struggling with refractory or relapsed CD30-positive peripheral T-cell lymphoma (PTCL).
Affirmed speaks out about the investigator-sponsored trial (IST) and the much-anticipated unveiling of its three dose-escalation cohorts. The University of Texas MD Anderson Cancer Center of AFM13 is the location where researchers conduct their studies. Scientists want to evaluate the increasing doses of cord-blood-derived NK cells.
They will also be checking out certain inferences about those cells when pre-complexed with AFM13. They plan to undertake three weekly infusions of AFM13 monotherapy as part of the process. The infusions are set to be conducted with patients struggling with refractory or recurrent CD30-positive lymphomas.